|
Name: Diclazepam (7-chloro-5-(2-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one
Type: Benzodiazepine
AKA: N/A
![Diclazepam (7-chloro-5-(2-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one image](https://grammasearch.com/dev/v2/aiimages/diclazepam_%287-chloro-5-%282-chloro-5-%282-chlorophenyl%29-1-methyl-1%2C3-dihydro-2h-benzo%5Be%5D%5B1%2C4%5Ddiazepin-2-one.png)
|
|
II. Natural Derivative
Synthetic substance, no natural derivative
 |
|
III. Chemical Profile (IUPAC name)
![Diclazepam (7-chloro-5-(2-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one image](/dev/v2/pages/pubchem_images/9829522.png)
|
|
IV. History
Diclazepam, a benzodiazepine analog, was first synthesized in the 1970s. It was developed to provide anxiolytic and sedative effects similar to other benzodiazepines but with variations in chemical structure. The compound's introduction was part of ongoing research into benzodiazepine derivatives for enhanced efficacy and safety. Diclazepam's use in the recreational drug market reflects broader trends in synthetic drug development and its associated regulatory challenges.
|
|
V. Legal Information
Diclazepam is a benzodiazepine used for its anxiolytic effects. It is controlled in various countries due to its potential for dependence and misuse. In the United States, it falls under broader benzodiazepine regulations, with similar controls in place globally. [Source: UNODC].
US Federal Schedule - I
Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Some examples of Schedule I drugs are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote.
Key US Federal Policies:
Controlled Substances Act. Public Law: Public Law 91-513 (text can be found on GovInfo) (https://www.dea.gov/drug-information/csa). Date enacted: October 27, 1970.
|
|
VI. Physical Effects
Diclazepam is a benzodiazepine with anxiolytic and sedative effects. It causes sedation, reduced heart rate, and impaired motor function. Short-term use is effective for managing anxiety and sleep disorders, but long-term use can lead to dependence, cognitive impairment, and significant health issues. Overdose risks include severe sedation, respiratory depression, and potential death. Safe use involves following prescribed dosages. Recent research explores its efficacy and associated risks.  |
|
VII. Psychological Effects
N/A
 |
|
VIII. Culture
Diclazepam is a benzodiazepine used for anxiety and sedation, classifying it as a downer. Short-term use alleviates anxiety and promotes relaxation, while long-term use can lead to dependence, tolerance, and cognitive impairment. Overdose risks include severe sedation, respiratory depression, and potentially fatal outcomes. Safe dosages are typically prescribed by medical professionals. Recent research highlights its effectiveness in anxiety management but warns of addiction risks. Physical effects include drowsiness, impaired coordination, and potential for respiratory depression.
 |